1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Cote d%Ivoire Pharmaceuticals and Healthcare Report Q2 2016

Cote d%Ivoire Pharmaceuticals and Healthcare Report Q2 2016

  • February 2016
  • -
  • Business Monitor International
  • -
  • 55 pages

BMI View: Cote d'Ivoire's pharmaceutical market will remain unattractive for multinationalpharmaceutical companies. This is particularly true for innovative drugmakers as the country lacks patentlegislation and a reimbursement regime. Furthermore, the country continues to suffer from politicalinstability which will act as a strong deterrent for investment. Over the long term, however, a rising noncommunicabledisease burden will provide opportunities for the sale of higher-value drugs, Roche hasalready made inroads into the oncology drug market. Growth in the healthcare sector will be supported byprogression towards an economic recovery, as well as the universal healthcare scheme launched in 2015.

Headline Expenditure Projections

- Pharmaceuticals: XOF259.97bn (USD436mn) in 2015 to XOF279.48bn (USD456mn) in 2016; +7.5%in local currency terms and 4.6% in US dollar terms. Forecast unchanged from previous quarter.

- Healthcare: XOF1,118.96bn (USD1.88bn) in 2015 to XOF1,230.21bn (USD2.01bn) in 2016; +9.9% inlocal currency terms and 6.9% in US dollar terms. Forecast in line with previous quarter.

Table Of Contents

Cote d%Ivoire Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Cote d`Ivoire 2014-2020) 7
SWOT 9
Industry Forecast 10
Pharmaceutical Market Forecast 10
Latest Updates 10
Table: Pharmaceutical Sales, Historical Data And Forecasts (Cote d`Ivoire 2012-2020) 12
Healthcare Market Forecast 13
Latest Updates 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Cote d`Ivoire 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Cote d`Ivoire 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Cote d`Ivoire 2012-2020) 17
Pharmaceutical Trade Forecast 18
Structural Trends 18
Table: Pharmaceutical Trade Data And Forecasts (Cote d`Ivoire 2014-2020) 20
Table: Pharmaceutical Trade Data And Forecasts local currency (Cote d`Ivoire 2014-2020) 20
Industry Risk Reward Index 21
Middle East and Africa Risk/Reward Index - Q2 2016 21
Côte d'Ivoire Risk/Reward Index 28
Rewards 28
Risks 29
Regulatory Review 30
Intellectual Property Issues 30
Pricing Regime 31
Reimbursement Regime 31
Market Overview 33
Healthcare Sector 34
Research and Development 36
Clinical Trials 36
Epidemiology 36
Competitive Landscape 40
Research-Based Industry 40
Table: Multinational Market Activity 40
Generic Drugmakers 41
Pharmaceutical Distribution 41
Demographic Forecast 44
Table: Population Headline Indicators (Cote d`Ivoire 1990-2025) 45
Table: Key Population Ratios (Cote d`Ivoire 1990-2025) 45
Table: Urban/Rural Population and Life Expectancy (Cote d`Ivoire 1990-2025) 46
Table: Population By Age Group (Cote d`Ivoire 1990-2025) 46
Table: Population By Age Group % (Cote d`Ivoire 1990-2025) 47
Glossary 49
Methodology 51
Pharmaceutical Expenditure Forecast Model 51
Healthcare Expenditure Forecast Model 51
Notes On Methodology 52
Risk/Reward Index Methodology 53
Index Overview 54
Table: Pharmaceutical Risk/Reward Index Indicators 54
Indicator Weightings 55

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.